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Despite decreasing mortality over the past decade, car-
diac surgery patients may experience significant post-
operative morbidity. Morbidity occurs because surgery 
itself carries a risk of iatrogenic harm, primarily as a 
result of ischaemia reperfusion injury (IRI)1 and the sys-
temic inflammatory response (SIR).2 Although several 
strategies have been developed to reduce IRI and SIR 
(e.g. minimising the effects of perfusion and ‘condition-
ing’ the heart to make it more resistant to injury),3 these 
harms of surgery are often responsible for potentially 
life-threatening post-operative complications and delays 
in discharge from hospital.
Cardiac surgery with conventional extracorporeal 
circulation (CECC) provokes a vigorous SIR due to acti-
vation of stress pathways associated with post-operative 
end-organ complications (e.g. heart failure, renal 
impairment and neurological dysfunction). SIR is trig-
gered by operative surgical trauma and IRI but is further 
exacerbated by the interaction of air, blood and syn-
thetic components in the CECC apparatus. Minimally 
invasive extracorporeal circulation (MiECC) systems 
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Abstract
Introduction: Despite low mortality, cardiac surgery patients may experience serious life-threatening post-operative 
complications, often due to extracorporeal circulation and reperfusion. Miniaturised cardiopulmonary bypass (minimally 
invasive extracorporeal circulation) has been developed aiming to reduce the risk of post-operative complications arising 
with conventional extracorporeal circulation.
Methods: The COMICS trial is a multi-centre, international, two-group parallel randomised controlled trial testing 
whether type II, III or IV minimally invasive extracorporeal circulation is effective and cost-effective compared to 
conventional extracorporeal circulation in patients undergoing elective or urgent coronary artery bypass grafting, aortic 
valve replacement or coronary artery bypass grafting + aortic valve replacement. Randomisation (1:1 ratio) is concealed 
and stratified by centre and surgical procedure. The primary outcome is a composite of 12 serious complications, 
objectively defined or adjudicated, 30 days after surgery. Secondary outcomes (at 30 days) include other serious adverse 
events (primary safety outcome), use of blood products, length of intensive care and hospital stay and generic health 
status (also at 90 days).
Status of the trial: Two centres started recruiting on 08 May 2018; 10 are currently recruiting and 603 patients have 
been randomised (11 May 2020). The recruitment rate from 01 April 2019 to 31 March 2020 was 40-50 patients/month. 
About 80% have had coronary artery bypass grafting only. Adherence to allocation is good.
Conclusions: The trial is feasible but criteria for progressing to a full trial were not met on time. The Trial Steering and 
Data Monitoring Committees have recommended that the trial should currently continue.
Keywords
cardiac surgery; extracorporeal circulation; cardiopulmonary bypass; randomised controlled trial
* See appendix 1 for author list.
Corresponding author:
Gianni D Angelini, Bristol Heart Institute, Bristol Royal Infirmary, 






integrate contemporary innovations in CPB technology 
into a strategy which aims to reduce SIR and improve 
end-organ protection during cardiac surgery. They 
comprise a closed circuit with biologically inert blood 
contact surfaces and reduced priming volume; a cen-
trifugal pump; a membrane oxygenator; a heat 
exchanger; a venous bubble trap or venous air remov-
ing device; a cardioplegia system and a shed-blood 
management device.4 Type IV hybrid modular MiECC 
systems (integrating a hard-shell venous reservoir as a 
stand-by component for immediate conversion to an 
open system) overcome safety concerns and unex-
pected intraoperative perfusion scenarios; thus, they 
are compatible with every cardiac surgical procedure.5
Four meta-analyses6–9 (with overlapping included 
RCTs; one also compared MiECC with off-pump coro-
nary artery bypass grafting9 (CABG)) have reported 
substantial benefits of MIECC for 30-day mortality, 
stroke, myocardial infarction (MI), post-operative atrial 
fibrillation and renal dysfunction. No harms were 
reported. The diversity of MiECC systems, patients and 
outcomes, and the poor methodological quality of many 
of the randomised clinical trials (RCTs) included in 
these reviews, undermines the strength of this evidence 
and most hospitals continue to use CECC.9 Nevertheless, 
the potential benefit of MiECC highlights the urgent 
need to evaluate this technology in a large, high-quality 
RCT. The proposed trial will evaluate MiECC systems 
that conform to an established typology,5 recruit patients 
having the most common cardiac surgery operations, 
report important clinical outcomes and includes fea-
tures to minimise bias.
Methods
Trial design and population
This COMICS trial is an international, multi-centre, ran-
domised, controlled parallel group trial to investigate the 
effects of using MiECC in all patients having elective or 
urgent coronary artery bypass grafting (CABG), aortic 
valve replacement (AVR) or CABG + AVR using 
extracorporeal circulation without circulatory arrest 
(Figure 1). The trial aims to test the hypothesis that 
MiECC is effective and cost-effective compared to CECC 
for most cardiac surgery operations requiring extracor-
poreal circulation without circulatory arrest. The trial 
includes a pilot and main trial phase.
The trial has three specific objectives:
1. To estimate the difference between groups in the 
proportion of participants experiencing the pri-
mary outcome (a composite of serious complica-
tions) up to 30 days after randomisation.
2. To compare secondary outcomes between 
groups: serious adverse events (SAE; events 
which result in death, are life threatening, 
require hospitalisation or prolongation of hos-
pitalisation, result in persistent or significant 
disability or incapacity) not included in the 
primary outcome, red blood cells (RBC) and 
other blood products transfused; duration of 
cardiac ICU and hospital stay following the 
index admission; resource use, generic health 
status.
3. To estimate the cost-effectiveness of MiECC 
compared to CECC.
Eligibility criteria
The trial is recruiting patients undergoing CABG, AVR 
or CABG + AVR. Cardiac surgery centres in Germany, 
Greece, Italy, Saudi Arabia, Switzerland, Turkey and the 
United Kingdom are participating. Additional centres 
in the United Kingdom, Germany and Canada are in 
set-up.
Inclusion criteria
Patients are eligible if all the following apply:









90 days after surgery
EQ-5D-5L 
MiECC 
Type II-III or IV MiECC 
system  
(n=1,750) 




90 days after surgery
EQ-5D-5L 
All patients having CABG, AVR or 
CABG+AVR surgery using extra-corporeal 
circulation without circulatory arrest 
Eligible patients providing written informed 
consent 
Randomise prior to surgery 
(stratified by type of surgery) 
Figure 1. Trial schema.
CABG: coronary artery bypass grafting; AVR: aortic valve replacement; 
CECC: conventional extracorporeal circulation; MiECC: minimally 
invasive extracorporeal circulation; SAE: serious adverse event.
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2. Undergoing any elective or urgent CABG, AVR 
or CABG + AVR surgery, using extracorporeal 
circulation without circulatory arrest.
Exclusion criteria
Patients are ineligible if any of the following apply:
1. Requirement for emergency or salvage operation.
2. Requirement for major aortic surgery (e.g. aortic 
root replacement).
3. 3 Contraindication or objection (e.g. Jehovah’s 
Witnesses) to transfusion of blood products.
4. Congenital or acquired platelet, RBC, or clotting 
disorders (patients with iron deficient anaemia 
only are not excluded).
5. Inability to give informed consent for the trial 
(e.g. learning or language difficulties).
Patient approach and consent
Potential trial participants are identified before their 
surgery from clinic lists and inpatient referrals. All 
potential participants receive an invitation letter and a 
patient information leaflet (PIL) describing the trial and 
are given time to discuss their participation with others 
outside the research team (e.g. relatives or friends) if 
they wish. Before their operation, patients are seen by a 
member of the local research team answers any ques-
tions, confirms eligibility and takes written informed 
consent if the patient is willing.
Trial interventions
Minimally invasive extracorporeal circulation (MiECC; experi-
mental intervention). MiECC systems have evolved in a 
modular fashion, to address safety, volume and blood 
management issues. Systems have been classified 
according to their features (Types 1, II, III and IV).4 
Centres may use any MiECC circuit which uses CE-
marked components (or the country-specific required 
standards outside the European Community) and 
which have features consistent with Type II, III or IV 
criteria.
Conventional extracorporeal circulation (CECC; comparator 
intervention). CECC should comprise (required compo-
nents) standard oxygenator, roller pump, hard-cell res-
ervoir, arterial filter, shed-blood suctions, any of a 
range of venting options, uncoated tubing and a cell-
saver device. The following optional/alternative com-
ponents can be integrated (and recorded accordingly): 
coated oxygenator, coated tubing and centrifugal 
pump. The following components are prohibited: soft-
cell reservoir and vacuum-assisted venous drainage 
(these are advanced components which make CECC 
resemble a custom-made MiECC circuit).
Aspects of surgery common to both MiECC and CECC. Other 
aspects of the operations may vary by operation and 
centre but must be used consistently in the MiECC and 
CECC groups. For example, surgeons may use differ-
ent cardioplegia solutions at different temperatures in 
different centres or for different operations. However, 
a surgeon carrying out one type of operation in one 
centre, for example, CABG in Centre A, must use the 
same cardioplegia solution for both MiECC and CECC. 
We are collecting operative details to characterise and 
report these variations. We believe such diversity in 
practice in the trial will create greater confidence in the 
applicability of the findings to a potential user’s clinical 
setting.
Randomisation
Randomisation is performed using a secure Internet-
based randomisation system, (Sealed Envelope) and is 
stratified by centre and surgical procedure (i.e. CABG, 
AVR, CABG + AVR). Participants are allocated in a 1:1 
ratio to either MiECC or CECC. Randomisation takes 
place as close to surgery as possible and is performed by 
an authorised member of the local research team. 
Information to identify a participant and to confirm eli-
gibility must be entered before a number is assigned (i.e. 
concealed randomisation).
Blinding and other features to minimise 
bias
The trial includes features designed to minimise bias.10 
Participants are blinded to the allocation. Documentary 
evidence is being sought wherever possible for events 
that qualify for the primary outcome; other events will 
be adjudicated. The 30-day primary outcome minimises 
loss to follow-up. Reporting bias will be minimised by a 
statistical analysis plan finalised before the database is 
locked.
Trial outcomes
Primary outcome. The primary outcome is a composite of 
post-operative SAEs occurring up to 30 days after ran-
domisation following the index admission. All SAEs 
that qualify for the primary outcome are objectively 
defined or will be adjudicated. The following events 
qualify:
(a) All-cause mortality up to 30 days after surgery




(e) AKI (Acute kidney injury–an acute increase in 
serum creatinine > 26.4 μmol/L or a percentage 
increase in serum creatinine of more than or 
equal to 50%) Network criteria for stage 3 AKI11
(f) Reintubation
(g) Tracheostomy
(h) Mechanical ventilation for >48 hours, including 




(k) Sternal wound infection with dehiscence
(l) Septicaemia confirmed by microbiology
Events will be documented as follows: suspected MI 
by serum troponin concentrations and electrocardio-
graph recording (ECG); stroke from brain imaging (CT 
or MRI) report and record of new onset focal or gener-
alised neurological deficit; gut infraction by laparotomy 
or post-mortem; other events from the medical record. 
Equivocal events will be adjudicated.
Secondary outcomes are as follows:
(a) All-cause mortality up to 30 days after surgery
(b) Other SAEs up to 30 days after surgery (primary 
safety outcome)
(c) Units of RBC transfused up to 30 days after sur-
gery
(d) Other blood products transfused up to 30 days 
after surgery
(e) Time to discharge from cardiac ICU during the 
index admission
(f) Time to discharge from hospital following the 
index admission
(g) Delirium in ICU, assessed with the Intensive 
Care Delirium Screening Checklist (ICDSC)12 
for up to 5 days (only collected at some centres).
(h) Generic health status using the EuroQol 5-level 
health status questionnaire (EQ-5D-5L)13 at 30 
and 90 days after randomisation
(i) Health resources and associated costs up to 
90 days after randomisation (UK centres only)
Data collection
Participants are followed up twice, at 30 days and 90 days 
after surgery. Questions elicit information about SAEs 
(including readmissions) experienced since discharge 
up to 30 days after the date of surgery. Generic health 
status is assessed around both 30 and 90 days. The 
schedule of data collection is outlined in Table 1. Data 
are collected from participants or their medical records, 
entered into a bespoke database and stored on a secure 
server.
Sample size
The trial is powered for the primary composite out-
come. The transfusion indication threshold reduction 2 
trial (TITRe2) trial, carried out in 17 UK centres, 
showed a rate of 15-18% in the post-operative SAEs 
qualifying for the primary outcome in participants 
receiving CECC, depending on the type of surgery 
received (CABG, AVR, CABG + AVR).14 Pooled esti-
mates from previous meta-analyses of the effects of 
MiECC versus CECC have reported benefits of MiECC 
for a range of clinical outcomes: odds ratios for 30-day 
mortality, 0.586 0.407 0.46;9 for stroke, 0.256 0.407 0.40;9 
for MI, 0.33,7 0.40;9 for post-operative atrial fibrillation, 
0.62;9 renal dysfunction 0.47.9 A smaller but still clini-
cally important target relative difference, that is, risk 
ratio of 0.75, was chosen for the trial. In order to detect 
a risk ratio of ⩽0.75 with 90% power and 5% signifi-
cance (two-tailed), 2,504 to 3,258 participants are 
required, depending on the numbers recruited to dif-
ferent surgical strata. We propose to recruit 3,500 par-
ticipants to allow for uncertainty in the assumptions 
underpinning this calculation.
SAEs
SAEs are considered in three categories: SAEs that 
qualify for the primary outcome, other SAEs that are 
known complications of cardiac surgery, and SAEs that 
are not known complications of cardiac surgery. The 
latter will be subject to expedited reporting to the Lead 
Coordinating Centre. Expedited reporting will also 
include all fatal events.
Governance
UK sites have ethics approval through the UK Integrated 
Research Application System (222991). Non-UK sites or 
Table 1. 
T1 T2 T3 T4 T5
Date PIS sent, date approached, age, 
sex, type of procedure
  
Eligibility check, reason for ineligibility   
Consent, reason for declining   
Baseline data collection   
Randomisation details   
Primary outcome events    
Blood products transfused    
Serious adverse events    
Generic health status (EQ-5D-5L)   
T1: Pre-consent (anonymised). T2: Pre-admission clinic/day before 
operation.
T3: During index admission. T4: 30 days. T5: 90 days.
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countries are responsible for following their own local 
governance processes and obtaining the necessary 
approvals. The University of Bristol is acting as the 
sponsor for UK sites and as the central coordinating 
centre for non-UK sites.
Statistical analysis
Statistical analysis is the responsibility of the Bristol 
Trials Centre (BTC). A final statistical analysis plan will 
be written, consistent with the CONSORT guidelines, 
including the extension for non-pharmacologic treat-
ment interventions,15 and signed off before any analysis 
takes place.
Analyses of all outcomes apart from the primary 
safety outcome will be conducted according to the 
intention-to-treat (ITT) principle, with participants 
analysed according to the groups to which they were 
randomised. A per-protocol (PP) analysis, only includ-
ing participants who received the intervention to which 
they were allocated, will be considered for the primary 
outcome if there are a considerable number of protocol 
deviators. The safety population will consist of all par-
ticipants, where participants will be included according 
to the intervention they received.
Primary outcome analysis. The primary outcome will be 
assessed using a generalised linear model (GLM) to 
compare trial arms in terms of the risk ratio of experi-
encing a qualifying SAE up to 30 days after surgery, 
adjusting for centre and operative procedure.
Secondary outcome analyses. Binary secondary outcomes 
(all-cause mortality at 30 days after surgery; any other 
SAE at 30 days after surgery; any RBC transfusion; any 
platelet transfusion; any fresh frozen plasma transfu-
sion) will be assessed separately, using GLMs as for the 
primary outcome. The total number of units of blood 
products transfused will also be analysed using linear 
regression, adjusting for centre and operative proce-
dure, for all blood products.
Time to death, time to discharge from CICU and 
time to discharge from hospital will be assessed using 
Cox proportional hazards models to compare the trial 
arms, adjusting for centre and operative procedure, for 
both analyses. Median survival with 95% confidence 
intervals will be estimated by trial arm and overall for 
both analyses.
Generic health status (EQ-5D-5L) will be analysed 
using a linear mixed effects model. Mean QoL scores 
and 95% CIs will be summarised at baseline, 30 days and 
90 days.
Occurrence and frequency of all safety events (SAEs 
that do not qualify for the primary outcome) will be 
summarised by trial arm and overall.
Subgroup analyses. Subgroup analyses will be carried out 
for the primary outcome to compare the trial arms 
across each level of the following characteristics:
•	 Age (dichotomised by the median)
•	 Sex (male, female)
•	 Operation type (CABG, AVR and CABG + AVR)
•	 EuroSCORE (dichotomised by the median)
•	 Preoperative renal dysfunction (dichotomised by 
the median)
•	 Preoperative Hb (dichotomised by the median)
All subgroup analyses will be interpreted with caution 
and treated as hypothesis-generating.
Cost-effectiveness analysis. The cost-effectiveness of 
MiECC compared to CECC will be estimated for COM-
ICS participants recruited in England (approximately 
600 participants), using quality-adjusted life years as the 
outcome measure estimated using the EQ-5D-5L, which 
can be mapped on to ‘valuations’.16
Costs of resource use for English participants will be 
estimated using linked Hospital Episode Statistics (HES) 
data and information from a previous trial.13 We will 
calculate average costs and outcomes associated with 
MiECC and CECC and produce an incremental cost per 
quality adjusted life year (QALY) gained with MiECC 
compared to CECC. If there are differences in mortality 
between trial arms, then costs and outcomes will be 
extrapolated to a longer time horizon. Scenario analyses 
will use EQ-5D-5L data from all participants and cost 
data from English participants.
Status of the trial
Two centres started to recruit on 08 May 2018. Ten cen-
tres are currently recruiting; another centre recruited 
for 14 months but stopped participating for reasons 
unrelated to the trial. About 40-50 patients were ran-
domised per month from 01 April 2019 to 31 March 
2020 with over 600 now randomised. About 80% of par-
ticipants have had CABG only. Primary outcomes are 
available in the database for 85%, recognising that these 
may still have to be entered for recent recruits. Adherence 
to randomised allocation is good (99%).
Discussion/challenges
There have been significant challenges in setting up the 
trial and achieving the rate of recruitment required to 
complete the trial in a feasible duration (scheduled to 
recruit for 3 years from September 2020). A joint meet-
ing of the Trial Steering and Data Monitoring Committees 
reviewed progress against criteria for continuing to the 
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main trial in December 2019, 18 months after starting 
the pilot: ⩾16 centres recruiting; ⩾750 participants ran-
domised; >90% adherence to the allocated intervention. 
These criteria were not met, primarily due to fewer than 
expected centres joining the trial especially during 2018. 
Nevertheless, the Committee chairs recommended con-
tinuing for a further 6-9 months, aiming to increase the 
recruitment rate and obtaining funding for the main 
trial. Additional centres are currently being set up and an 
application for funding has been submitted. New centres 
are welcome to join the trial (please email the contact 
address provided for further details).
Negotiating contracts with each participating site 
has been the most serious challenge. The contract 
describes indemnity arrangements, key responsibili-
ties of different parties, intellectual property and data 
ownership, data sharing and publication policy, even if 
no funding is offered. The main obstacles have been 
indemnity (the coordinating centre is not providing 
any), intellectual property ownership (owned by the 
coordinating centre) and the legal system under which 
any disputes would be considered (both governing law 
and jurisdiction), which have prevented some centres 
from taking part.
Some centres have been unable to take part because 
there is no funding yet to reimburse their research costs; 
one potential centre considered this unethical. Award of 
funding would address this challenge and potentially 
increase recruitment in centres already recruiting.
The capital cost of adopting MiECC has been a bar-
rier for centres wanting to use it. Adopting MiECC 
also requires entire surgical teams (surgeon, anaesthe-
tist and perfusion team) to agree. MiECC also has 
higher consumable costs, although these may poten-
tially be offset by clinical benefits (see above). 
European guidelines recommend that MiECC should 
be considered instead of CECC to increase the bio-
compatibility of extracorporeal circulation technol-
ogy used in cardiac surgery (class of recommendation 
IIA, level of evidence B).17
The COMICS trial is already the largest randomised 
trial of MiECC compared to CECC in patients having 
most cardiac surgery operations requiring extracorpor-
eal circulation without circulatory arrest. The COMICS 
trial will have substantial health and socioeconomic 
impacts. It will quantify the effects of MiECC versus 
CECC on a range of important clinical outcomes (major 
post-operative complications, mortality, etc.), health 
resource use (blood product use, intensive care unit 
and hospital stay, etc.), health-related quality of life 
(EQ-5D-5L) and QALYs.
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